Form 4: Alnylam Pharmaceuticals Executive Pushkal Garg Reports Stock Transactions

Pushkal Garg, CMO & EVP of Development & Medical Affairs at Alnylam Pharmaceuticals, reports stock sales and option exercises under a pre-arranged trading plan.

Summary

• Pushkal Garg, a key executive at Alnylam Pharmaceuticals, filed a Form 4 detailing recent transactions involving the company's stock.
• On March 21, 2025, Garg sold 4,321 shares of common stock at $285 per share.
• On March 24, 2025, Garg exercised a stock option for 5,445 shares at an exercise price of $42.22 and then sold those shares at $300 per share.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on September 11, 2024.
• Following these transactions, Garg directly owns 20,221 shares of Alnylam common stock.
• Garg also has indirect ownership of 431 shares through a managed account and 250 shares through a trust where his spouse is a co-trustee, but he disclaims beneficial ownership of the trust shares.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the transactions are part of a pre-planned trading strategy and do not necessarily indicate a change in the executive's confidence in the company.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which is a legal and transparent way for insiders to trade company stock.

Industry Context

Insider transactions are routinely monitored and reported, providing transparency into executive sentiment and potential future performance. The use of a 10b5-1 plan suggests a planned and orderly approach to stock transactions.

Comparison to Industry Standards

• Executive stock transactions are common in publicly traded pharmaceutical companies like Alnylam.
• Companies such as Amgen, Gilead Sciences, and Biogen also see regular Form 4 filings from their executives.
• The use of Rule 10b5-1 trading plans is a standard practice among executives to avoid accusations of insider trading.

Stakeholder Impact

• The stock transactions may have a minor impact on shareholders due to the increased volume of shares traded.
• The transactions do not appear to have a direct impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Alnylam Pharmaceuticals, Pushkal Garg, stock sale, stock option, Form 4, insider trading, Rule 10b5-1, executive compensation